Document is current
Any future updates will be listed below
-
Authors
Ohara, Makoto
Yokoyama, Hiroki
Seino, Hiroaki
Fujikawa, Tomoki
Kohata, Yo
Takahashi, Noriyuki
Irie, Shunichiro
Terasaki, Michishige
Mori, Yusaku
Fukui, Tomoyasu
Yamagishi, Sho-ichi
- License Information
-
More Information
Article History
Received: 2 August 2024
Accepted: 3 April 2025
First Online: 15 April 2025
Declarations
:
: The study protocol was approved by the Ethics Committee of Showa University and adhered to the principles of the Declaration of Helsinki and current legal regulations in Japan. After thoroughly explaining the study protocol, written informed consent was obtained from all participants.
: Not applicable.
: MO has received lecture fees from Eli Lilly Japan K.K. HS has received lecture fees from Astellas Pharma Inc., Novartis Pharmaceuticals Co., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., MSD K.K., and Sanofi K.K. as well as received research funds from Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., YL Biologics Ltd., and Sanofi K.K. YM holds an endowed chair funded by Ono Pharmaceutical Co., Ltd. and Nippon Boehringer Ingelheim Co., Ltd. SY has received lecture fees from Eli Lilly Japan K.K., Bayer Yakuhin, Ltd., Sanofi K.K., and Novo Nordisk Pharma, Japan.
